Sun Pharmaceutical Moves To Buy Taro In $450 Million Deal
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical has signed a definitive agreement to acquire Haifa, Israel-based Taro Pharmaceutical Industries in a deal valued at more than $450 million, the companies announced May 21
You may also be interested in...
Sun Set To Get Taro Deal Over The Line, 17 Years After First Trying
More than a decade after a renewed bid to take control of Taro failed, Sun Pharma is set to take full control of the Israeli-based derma specialist, which has seen material growth and much controversy in the US under Sun’s ownership.
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2
Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair
MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2